Research
Hormonal
Retatrutide (LY3437943) is relatively safe and supports once-weekly dosing.
Practitioners can consider retatrutide as a potentially safe option for treatment with a convenient dosing schedule.
StrongSupportsmedium confidence
Retatrutide was relatively safe and pharmacokinetics support once-weekly dosing.
Why this rating
Based on the phase 1b clinical trial design mentioned in the abstract.
Source
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023
otherCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →